GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Earnings per Share (Diluted)
Switch to:

Biogen (MEX:BIIB) Earnings per Share (Diluted)

: MXN425.37 (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was MXN48.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was MXN425.37.

Biogen's EPS (Basic) for the three months ended in Mar. 2023 was MXN48.49. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was MXN426.92.

Biogen's EPS without NRI for the three months ended in Mar. 2023 was MXN48.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was MXN425.37.

During the past 12 months, Biogen's average EPS without NRIGrowth Rate was 120.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -12.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 1.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.90% per year.

During the past 13 years, Biogen's highest 3-Year average EPS without NRI Growth Rate was 205.20% per year. The lowest was -66.00% per year. And the median was 26.65% per year.


Biogen Earnings per Share (Diluted) Historical Data

The historical data trend for Biogen's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 423.72 592.58 493.32 213.35 406.88

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Earnings per Share (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.02 145.65 157.70 73.89 48.13

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Earnings per Share (Diluted), along with its competitors' market caps and Earnings per Share (Diluted) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Earnings per Share (Diluted) Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Earnings per Share (Diluted) distribution charts can be found below:

* The bar in red indicates where Biogen's Earnings per Share (Diluted) falls in comparison to its industry or sector. The grey bar indicates the Earnings per Share (Diluted)'s extreme value range as defined by GuruFocus.



Biogen Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Biogen's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(59402.362-0)/146.000
=406.87

Biogen's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (Q: Mar. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(6991.897-0)/145.200
=48.15

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN425.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Biogen  (MEX:BIIB) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biogen Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Biogen's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines